Influence of heart rate reduction on heart injury that happens during interventional coronary procedure and stent deployment in patients with coronary disease

ISRCTN ISRCTN59609019
DOI https://doi.org/10.1186/ISRCTN59609019
Secondary identifying numbers 2010/5
Submission date
29/06/2018
Registration date
06/07/2018
Last edited
05/08/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

There is no data that heart rate reduction reduces periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention (angiography of coronary vessels with subsequent stent implantation in narrowed segments in order to reestablish normal blood flow through coronary vessels). Ivabradine is an established drug that reduces heart rate (HR) and subsequently alleviates symptoms of angina (heart pain due to coronary stenoses). In this study we sought to determine whether HR reduction via ivabradine attenuates or reduces the amount of myocardial injury that in small extent occurs during stent implantation.

they were eligible if heart rate was above 70/min and afterwards randomized in two groups (ivabradine group and control group)
40 patients with stable angina and resting heart rate above 70 beats per minute (bpm) were assigned to ivabradine 5 mg twice daily. The control group consisted of 40 patients with resting heart rate above 70 bpm. All patients were included 1 month before scheduled intervention. After admission troponin I levels (blood marker of myocardial damage or injury) were measured before the procedure and after 24 hours. We also collected data of any change in symptoms in both groups.

The benefit was that patients were examined more frequently; also the clinical benefit of treatment with ivabradine was previously proven and the prescription was in line with guidelines for treatment of patients with ischemic heart (coronary) disease. There were no potential additional risks for included patients.

Contact information

Dr Franjo Naji
Scientific

Ljubljanska ulica 5
Maribor
2000
Slovenia

ORCiD logoORCID ID 0000-0002-1425-4189
Phone +386 (0)23212371
Email franjo.naji@yahoo.com

Study information

Study designSingle-center interventional study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleEffect of heart rate reduction on periprocedural myocardial injury and angina symptoms in elective patients with coronary disease undergoing coronary intervention
Study objectivesHeart rate reduction via ivabradine treatment reduces periprocedural myocardial injury and reduces symptoms in patients with stable coronary disease undergoing interventional coronary procedure.
Ethics approval(s)Institutional ethics committee University Clinical center Maribor, 05/05/2010, approval Nr: 092-30/2010
Health condition(s) or problem(s) studiedIschemic heart disease with stable angina
InterventionAfter inclusion criteria were met patients were invited to participate in study. Informed consent was obtained, and patients were instructed to attend first visit one month before planned procedure. At first visit heart rate was reassessed. Patients were asked about their usual therapy adherence and then instructed to rest for five minutes. 12-lead ECG was recorded and if eligible (heart rate > 70 bpm) patients were then randomly assigned to one of two groups. Patients were randomized so that the first patient was in group 1 and the second was in group 2 and so on. Patients in group 1 were prescribed ivabradine 5 mg twice daily on top of their standard therapy and patients in group 2 received no additional treatment. Treatment with ivabradine wasn't stopped after the study conclusion. There was no long-term follow-up or additional visits for the patients included in the protocol, patients had regular visits based on their clinical characteristics.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase IV
Drug / device / biological / vaccine name(s)Ivabradine
Primary outcome measurePeriprocedural myocardial injury, measured using cardiac troponin I assay (Siemens Healthcare Diagnostics) from blood samples at admission (before the procedure) and 24 hours after the procedure
Secondary outcome measuresSymptoms of angina, assessed with the number of angina attacks (chest pain) per week, on the day of inclusion and 1 month after the inclusion
Overall study start date08/01/2010
Completion date06/04/2016

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants80
Total final enrolment78
Key inclusion criteria1. Patients scheduled for elective PCI
2. Suspected or established coronary artery disease
3. Presence of sinus rhythm
4. Resting heart frequency above 70 beats per minute
Key exclusion criteria1. Previous pacemaker implantation
2. Symptoms and signs of heart failure
3. Ejection fraction of left ventricle below 50%
4. Levels of creatinine above upper level of normal (ULN)
5. Already treated with ivabradine
Date of first enrolment17/05/2010
Date of final enrolment18/07/2014

Locations

Countries of recruitment

  • Slovenia

Study participating centre

University clinical center Maribor
Ljubljanska 5
2000 Maribor
2000
Slovenia

Sponsor information

University clinical center Maribor
Hospital/treatment centre

Dpt of cardiology
Ljubljanska 5
Maribor
2000
Slovenia

Website www.ukc-mb.si
ROR logo "ROR" https://ror.org/02rjj7s91

Funders

Funder type

Industry

Servier

No information available

Results and Publications

Intention to publish date01/08/2018
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planThe trialists plan to publish the data in an original article in a peer-reviewed journal with an impact factor as soon as possible.
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Dr Franjo Naji (franjo.naji@yahoo.com) in anonymised form in an Excel table. The decision to share data depends on the type of inquiry and person involved. No special consent of patients to share the data.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Abstract results Presented at ESC Congress 2014 30/08/2014 05/08/2021 No No
Results article 18/03/2021 05/08/2021 Yes No

Editorial Notes

05/08/2021:The following changes have been made:
1. Publication reference added.
2. The abstract link has been mved from the publication and dissemination plan to the outputs table.
06/11/2019: The following changes have been made:
1. Conference abstract link added to publication and dissemination plan.
2. The final enrolment number was added from the abstract.